Is VTRS or MANE more profitable?

Veradermics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Veradermics' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Veradermics N/A N/A N/A

Is MANE or ASND more profitable?

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Ascendis Pharma A/S 57.87% N/A -8.37%

Is MANE or BBIO more profitable?

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A BridgeBio Pharma -124.42% N/A -65.81%

Do analysts rate MANE or RDY?

Veradermics currently has a consensus price target of $114.20, suggesting a potential downside of 12.06%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradermics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Veradermics (MANE) Competitors

$129.86 +0.12 (+0.09%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$129.57 -0.29 (-0.22%)

As of 07/2/2026 07:59 PM Eastern

Compare

MANE vs. VTRS, GMAB, ASND, BBIO, and RDY

Should you buy Veradermics stock or one of its competitors? MarketBeat compares Veradermics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradermics include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Veradermics compare to Viatris?

Viatris (NASDAQ:VTRS) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Veradermics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Veradermics	N/A	N/A	N/A

79.9% of Viatris shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Veradermics has lower revenue, but higher earnings than Viatris. Veradermics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.36	-$3.51B	-$0.26	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

In the previous week, Viatris had 4 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Viatris and 0 mentions for Veradermics. Viatris' average media sentiment score of 0.73 beat Veradermics' score of 0.00 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Positive
Veradermics	Neutral

Viatris currently has a consensus price target of $17.50, suggesting a potential upside of 4.79%. Veradermics has a consensus price target of $114.20, suggesting a potential downside of 12.06%. Given Viatris' higher probable upside, equities analysts clearly believe Viatris is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Viatris beats Veradermics on 10 of the 13 factors compared between the two stocks.

How does Veradermics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Genmab A/S presently has a consensus target price of $38.21, suggesting a potential upside of 34.04%. Veradermics has a consensus target price of $114.20, suggesting a potential downside of 12.06%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Genmab A/S had 5 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Genmab A/S and 0 mentions for Veradermics. Genmab A/S's average media sentiment score of 0.69 beat Veradermics' score of 0.00 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Genmab A/S	Positive
Veradermics	Neutral

Genmab A/S has a net margin of 21.05% compared to Veradermics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Veradermics	N/A	N/A	N/A

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Veradermics	N/A	N/A	N/A	-$1.32	N/A

Summary

Genmab A/S beats Veradermics on 14 of the 14 factors compared between the two stocks.

How does Veradermics compare to Ascendis Pharma A/S?

Veradermics (NYSE:MANE) and Ascendis Pharma A/S (NASDAQ:ASND) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Veradermics currently has a consensus target price of $114.20, indicating a potential downside of 12.06%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 7.61%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Veradermics has higher earnings, but lower revenue than Ascendis Pharma A/S. Veradermics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Ascendis Pharma A/S	$865.78M	19.78	-$258M	$8.67	31.66

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Ascendis Pharma A/S	57.87%	N/A	-8.37%

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Veradermics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 0 mentions for Veradermics. Ascendis Pharma A/S's average media sentiment score of 0.60 beat Veradermics' score of 0.00 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
Ascendis Pharma A/S	Positive

Summary

Ascendis Pharma A/S beats Veradermics on 10 of the 11 factors compared between the two stocks.

How does Veradermics compare to BridgeBio Pharma?

Veradermics (NYSE:MANE) and BridgeBio Pharma (NASDAQ:BBIO) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

Veradermics has higher earnings, but lower revenue than BridgeBio Pharma. Veradermics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
BridgeBio Pharma	$502.08M	30.11	-$724.93M	-$3.74	N/A

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 8 more articles in the media than Veradermics. MarketBeat recorded 8 mentions for BridgeBio Pharma and 0 mentions for Veradermics. BridgeBio Pharma's average media sentiment score of 0.63 beat Veradermics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
BridgeBio Pharma	Positive

Veradermics presently has a consensus price target of $114.20, indicating a potential downside of 12.06%. BridgeBio Pharma has a consensus price target of $92.90, indicating a potential upside of 20.35%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Veradermics on 9 of the 12 factors compared between the two stocks.

How does Veradermics compare to Dr. Reddy's Laboratories?

Veradermics (NYSE:MANE) and Dr. Reddy's Laboratories (NYSE:RDY) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Dr. Reddy's Laboratories has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	-$1.32	N/A
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81

Veradermics currently has a consensus price target of $114.20, suggesting a potential downside of 12.06%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Veradermics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

In the previous week, Veradermics' average media sentiment score of 0.00 equaled Dr. Reddy's Laboratories'average media sentiment score.

Company	Overall Sentiment
Veradermics	Neutral
Dr. Reddy's Laboratories	Neutral

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Dr. Reddy's Laboratories beats Veradermics on 8 of the 11 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceutical Preparations Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$5.43B	$791.45M	$5.20B	$23.53B
Dividend Yield	N/A	4.84%	16.10%	3.98%
P/E Ratio	-98.38	1.66	23.91	31.55
Price / Sales	N/A	118.32	166.89	21.70
Price / Cash	N/A	20.06	35.06	25.36
Price / Book	N/A	8.17	13.25	4.81
Net Income	N/A	-$3.71M	$113.80M	$1.07B
7 Day Performance	2.31%	2.59%	0.93%	0.56%
1 Month Performance	41.16%	4.41%	1.08%	4.54%
1 Year Performance	N/A	49.43%	10.03%	18.23%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE Veradermics	0.7491 of 5 stars	$129.86 +0.1%	$114.20 -12.1%	N/A	$5.43B	N/A	N/A	19
VTRS Viatris	2.7908 of 5 stars	$16.33 flat	$17.50 +7.2%	+80.5%	$19.02B	$14.30B	N/A	30,000	Gap Down
GMAB Genmab A/S	4.7856 of 5 stars	$26.11 -0.1%	$37.93 +45.3%	+39.7%	$16.28B	$3.72B	19.78	3,029	Analyst Forecast Gap Down
ASND Ascendis Pharma A/S	4.1432 of 5 stars	$260.75 flat	$295.39 +13.3%	+57.7%	$16.27B	$814.57M	30.08	1,189	Analyst Upgrade High Trading Volume
BBIO BridgeBio Pharma	2.7921 of 5 stars	$70.24 flat	$92.90 +32.3%	+76.6%	$13.76B	$502.08M	N/A	400	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. VTRS, GMAB, ASND, BBIO, and RDY

How does Veradermics compare to Viatris?

Summary

How does Veradermics compare to Genmab A/S?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Summary

How does Veradermics compare to BridgeBio Pharma?

Summary

How does Veradermics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. VTRS, GMAB, ASND, BBIO, and RDY

How does Veradermics compare to Viatris?

Is VTRS or MANE more profitable?

Do insiders and institutionals hold more shares of VTRS or MANE?

Which has preferable earnings and valuation, VTRS or MANE?

Does the media favor VTRS or MANE?

Do analysts prefer VTRS or MANE?

Summary

How does Veradermics compare to Genmab A/S?

Do analysts prefer GMAB or MANE?

Does the media favor GMAB or MANE?

Is GMAB or MANE more profitable?

Do institutionals and insiders believe in GMAB or MANE?

Which has higher valuation and earnings, GMAB or MANE?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Do analysts rate MANE or ASND?

Which has better valuation and earnings, MANE or ASND?

Is MANE or ASND more profitable?

Does the media favor MANE or ASND?

Summary

How does Veradermics compare to BridgeBio Pharma?

Is MANE or BBIO more profitable?

Which has stronger earnings and valuation, MANE or BBIO?

Do institutionals & insiders have more ownership in MANE or BBIO?

Does the media refer more to MANE or BBIO?

Do analysts recommend MANE or BBIO?

Summary

How does Veradermics compare to Dr. Reddy's Laboratories?

Which has stronger valuation and earnings, MANE or RDY?

Do analysts rate MANE or RDY?

Is MANE or RDY more profitable?

Does the media favor MANE or RDY?

Do institutionals & insiders believe in MANE or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools